Research programme: MRSA vaccine therapeutics - Bavarian Nordic/ Evaxion Biotech/Technical University of Denmark
Alternative Names: Methicillin-resistant Staphylococcus aureus vaccines - Bavarian Nordic/Evaxion Biotech/Technical University of Denmark; MVA-BN based MRSA vaccines - Bavarian Nordic/Evaxion Biotech/Technical University of DenmarkLatest Information Update: 28 Mar 2020
At a glance
- Originator Bavarian Nordic; Technical university of denmark
- Developer Bavarian Nordic; Evaxion Biotech
- Class Vaccines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Methicillin-resistant-Staphylococcus-aureus-infections in Denmark
- 04 Feb 2016 Early research in Methicillin-resistant Staphylococcus aureus infections in Denmark (unspecified route)
- 04 Feb 2016 Bavarian Nordic, Evaxion Biotech and the Technical University of Denmark agree to co-develop vaccine in Denmark for Methicillin-resistant Staphylococcus aureus infections